Table 3. Association of clinical variables and immunostaining of RasGRP3 with PSA relapse-free survival based on Cox proportional hazards regression models.
| Variable |
Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| HR (95% CI) | P-value | Adjusted HR (95% CI) | Adjusted P-value | |
| Preoperative PSA | ||||
| <10 vs ⩾10 | 0.812 (0.462–1.427) | 0.469 | 1.099 (0.557–2.169) | 0.784 |
| Gleason score | ||||
| ⩽6 vs ⩾7 | 2.209 (1.099–4.441) | 0.026 | 1.266 (0.591–2.715) | 0.544 |
| T stage | ||||
| ⩽2 vs ⩾3 | 2.496 (1.334–4.668) | 0.004 | 1.71 (0.844–3.462) | 0.136 |
| Lymph node status | ||||
| Positive vs negative | 1.077 (0.595–1.948) | 0.807 | 0.617 (0.318–1.196) | 0.153 |
| Surgical margin status | ||||
| Positive vs negative | 1.357 (0.756–2.435) | 0.306 | 1.262 (0.629–2.529) | 0.513 |
| RasGRP3 expression | ||||
| Positive vs negative | 9.257 (4.314–19.864) | <0.001 | 9.464 (4.147–21.596) | <0.001 |
Abbreviations: CI, confidence interval; HR, hazard ratio; RasGRP3, guanyl nucleotide-releasing protein for Ras 3.